CA125 is a gold standard for the diagnosis of ovarian cancer, however, its specificity is still relatively low in clinical application. Tumor formation and development process is often accompanied by abnormal glycosylation modification and changes in glycan structures. The different tumors have specifically abnormal glycan structures. In recent years, the technologies in glycoproteomics and glycomics, such as lectin microarrays and multiple mass spectrometry, are used to discover the small discrepancies of N- and O-linked glycan structures in CA125 of the different sources. These abnormal glycan structures could increase the specificity of CA125 for the diagnosis of ovarian cancer. In the past decade, the technologies of glycome were also used to directly analyze the subtle glycan structures in the serum and body fluid (ascites, vesicle fluid, etc.) from patients with ovarian cancer. The results showed that the N-linked glycan structures can effectively identify ovarian cancer patients and healthy volunteers, which may be new biomarkers with better sensitivity and specificity for the diagnosis of ovarian cancer. Trends in the development of biomarkers for ovarian cancer shifted from qualitative and quantitative studies of proteins, to identification and quantitative analysis of glycosylation modification and glycan structures of biomarkers. Taking the perspective of glycomics, the status and development trend of ovarian cancer biomarkers are reviewed and discussed in this paper.